Korean patent backs CollPlant (NASDAQ: CLGN) photocurable dermal filler
Rhea-AI Filing Summary
CollPlant Biotechnologies reported that the Korean Patent Office has allowed a patent application covering key aspects of its photocurable dermal filler technology, which is based on the company’s recombinant human collagen (rhCollagen) platform and is currently under development for the aesthetic market.
The patent covers a polymerizable rhCollagen-based solution, combined with components such as a hyaluronic acid filler, injected into sub‑epidermal tissue and polymerized in situ using external light activation to form a supportive scaffold for tissue augmentation and contour stability. Patent protection is expected to extend through 2039.
The company notes that this Korean allowance follows a recently granted Japanese patent for related photocurable dermal filler compositions and adds to existing patent protection in the United States, Europe, China, Brazil, Australia, and Israel. CollPlant highlights that this technology targets the global injectable soft‑tissue filler market, which it cites as exceeding $6 billion.
Positive
- None.
Negative
- None.
Insights
Korean patent allowance strengthens CollPlant’s global IP around its photocurable rhCollagen dermal filler platform but does not change near-term fundamentals on its own.
CollPlant reports a Korean Patent Office allowance for a photocurable dermal filler using rhCollagen and light-activated in situ polymerization. This extends the company’s intellectual property footprint in a strategically important aesthetic market and is expected to provide protection through
The technology targets injectable soft-tissue fillers by combining chemically modified rhCollagen with components including a hyaluronic acid-based filler, aiming for structural tissue support and long-term contour stability in the aesthetic market. The company references a global injectable soft-tissue filler market size exceeding
The allowance complements a recently granted Japanese patent and existing grants in the United States, Europe, China, Brazil, Australia, and Israel. Actual commercial impact will depend on successful completion of development, regulatory clearances, and market adoption, none of which are quantified in this disclosure.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K including the press release attached hereto (other than the third and fourth paragraphs of the press release) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791) and Form F-3 (File No. 333-238731 and 333-292640), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On February 26, 2026, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Attached hereto and incorporated by reference herein are the following exhibits:
| 99.1 | Press Release, dated February 26, 2026. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| COLLPLANT BIOTECHNOLOGIES LTD. | ||
| Date: February 26, 2026 | By: | /s/ Eran Rotem |
| Name: | Eran Rotem | |
| Title: | Deputy CEO and Chief Financial Officer | |
2
Exhibit 99.1
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
| ● | Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product Candidate |
REHOVOT, Israel, February 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company’s photocurable dermal filler technology currently under development for the aesthetic market.
The allowed patent application covers a polymerizable solution and its use in tissue augmentation. The composition is injected into a sub-epidermal tissue space and subsequently polymerized in situ using external light activation. This invention underpins CollPlant’s proprietary photocuring platform for dermal fillers.
“This patent allowance represents another important milestone in executing our strategy to expand the clinical and commercial applications of our rhCollagen platform into high-value aesthetic markets,” said Yehiel Tal, Chief Executive Officer of CollPlant. “South Korea is a strategically important market in aesthetic medicine, and strengthening our intellectual property position in this region further enhances the long-term value of our technology.”
Mr. Tal added, “Beyond skin lifting, our photocurable rhCollagen-based filler platform was designed to support structural tissue restoration. Upon light activation, the material forms a supportive scaffold intended to enhance long-term contour stability. The technology is designed not only to restore facial contours but also to provide a regenerative matrix that may promote tissue integration and durable structural improvement. With patent protection extending through 2039, we believe this innovation positions us to compete effectively, upon completion of development, in a global injectable soft-tissue filler market currently estimated to exceed $6 billion and continuing to grow.”
The polymerizable formulation comprises chemically modified rhCollagen together with additional constituents, including a hyaluronic acid-based filler component. The solution is engineered to exhibit viscosity suitable for extrusion through a surgical needle of at least 27-gauge at the temperature of use, while enabling post-injection contour modulation before, during or after light-induced curing.
The Korean patent allowance follows the recent grant of a Japanese patent covering, among other things, a photocurable dermal filler kit and related polymerizable compositions comprising chemically modified rhCollagen for use in tissue augmentation. These compositions are introduced into a sub-epidermal tissue space and induced to polymerize upon light activation. CollPlant’s photocuring technology is further protected by granted patents in the United States, Europe, China, Brazil, Australia, and Israel, with additional applications pending in other territories.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives, plans and strategies, including the potential benefits and advantages of a Korean patent, the estimated global injectable soft-tissue filler market size,, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. Further, The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com
FAQ
What did CollPlant Biotechnologies (CLGN) announce in its latest Form 6-K?
What technology is covered by CollPlant’s new Korean patent allowance?
How long could CollPlant’s Korean photocurable dermal filler patent protection last?
How does the Korean patent allowance fit into CollPlant’s global IP portfolio?
What market opportunity does CollPlant target with its photocurable dermal filler?
How does CollPlant’s rhCollagen platform relate to its aesthetic and regenerative products?
What strategic partnership related to dermal fillers has CollPlant disclosed?
Filing Exhibits & Attachments
1 documentPress Releases
